S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69

Revance Therapeutics Stock Forecast, Price & News

-0.37 (-2.88%)
(As of 11/29/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
851,448 shs
Average Volume
646,462 shs
Market Capitalization
$894.57 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RVNC News and Ratings via Email

Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Revance Therapeutics logo

About Revance Therapeutics

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.


Revance Therapeutics (NASDAQ:RVNC) Reaches New 52-Week Low at $12.96
November 26, 2021 |  americanbankingnews.com
Revance Therapeutics, Inc. (NASDAQ:RVNC) Short Interest Update
November 21, 2021 |  americanbankingnews.com
Revance Therapeutics (NASDAQ:RVNC) Shares Gap Down to $14.11
November 19, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$15.32 million
Book Value
$1.67 per share


Net Income
$-282.09 million
Net Margins
Pretax Margin




Free Float
Market Cap
$894.57 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.58 out of 5 stars

Medical Sector

166th out of 1,392 stocks

Pharmaceutical Preparations Industry

68th out of 670 stocks

Analyst Opinion: 4.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions

Is Revance Therapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Revance Therapeutics stock.
View analyst ratings for Revance Therapeutics
or view top-rated stocks.

How has Revance Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Revance Therapeutics' stock was trading at $17.97 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RVNC shares have decreased by 30.7% and is now trading at $12.46.
View which stocks have been most impacted by COVID-19

Are investors shorting Revance Therapeutics?

Revance Therapeutics saw a increase in short interest during the month of October. As of October 29th, there was short interest totaling 4,270,000 shares, an increase of 24.1% from the October 14th total of 3,440,000 shares. Based on an average daily trading volume, of 1,060,000 shares, the short-interest ratio is presently 4.0 days. Currently, 6.2% of the company's shares are sold short.
View Revance Therapeutics' Short Interest

When is Revance Therapeutics' next earnings date?

Revance Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, February 28th 2022.
View our earnings forecast for Revance Therapeutics

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) issued its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.05. Revance Therapeutics had a negative net margin of 470.81% and a negative trailing twelve-month return on equity of 128.23%. During the same quarter in the prior year, the firm earned ($1.34) earnings per share.
View Revance Therapeutics' earnings history

What price target have analysts set for RVNC?

5 brokerages have issued 1 year target prices for Revance Therapeutics' shares. Their forecasts range from $17.00 to $36.00. On average, they anticipate Revance Therapeutics' stock price to reach $25.20 in the next year. This suggests a possible upside of 102.2% from the stock's current price.
View analysts' price targets for Revance Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Revance Therapeutics' key executives?

Revance Therapeutics' management team includes the following people:
  • Mark J. Foley, Chief Executive Officer & Director
  • Dustin Sjuts, President
  • Abhay Joshi, COO & President-Research & Development
  • Tobin C. Schilke, Chief Financial Officer
  • Azita Nejad, Senior Vice President-Technical Operations

What is Mark Foley's approval rating as Revance Therapeutics' CEO?

7 employees have rated Revance Therapeutics CEO Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among Revance Therapeutics' employees.

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (4.57%), ArrowMark Colorado Holdings LLC (3.91%), Jennison Associates LLC (2.90%), Polar Capital Holdings Plc (2.43%), Bamco Inc. NY (1.94%) and Wellington Management Group LLP (1.70%). Company insiders that own Revance Therapeutics stock include Aubrey Rankin, Dwight Moxie and Mark J Foley.
View institutional ownership trends for Revance Therapeutics

Which major investors are selling Revance Therapeutics stock?

RVNC stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Goldman Sachs Group Inc., ArrowMark Colorado Holdings LLC, Rothschild & Co. Asset Management US Inc., Dimensional Fund Advisors LP, Teachers Retirement System of The State of Kentucky, Cubist Systematic Strategies LLC, and New York State Common Retirement Fund. Company insiders that have sold Revance Therapeutics company stock in the last year include Aubrey Rankin, and Dwight Moxie.
View insider buying and selling activity for Revance Therapeutics
or view top insider-selling stocks.

Which major investors are buying Revance Therapeutics stock?

RVNC stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Polar Capital Holdings Plc, Moors & Cabot Inc., HighTower Advisors LLC, Bamco Inc. NY, Alliancebernstein L.P., Jennison Associates LLC, and Granahan Investment Management Inc. MA.
View insider buying and selling activity for Revance Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Revance Therapeutics?

Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Revance Therapeutics' stock price today?

One share of RVNC stock can currently be purchased for approximately $12.46.

How much money does Revance Therapeutics make?

Revance Therapeutics has a market capitalization of $894.57 million and generates $15.32 million in revenue each year. The biopharmaceutical company earns $-282.09 million in net income (profit) each year or ($4.49) on an earnings per share basis.

How many employees does Revance Therapeutics have?

Revance Therapeutics employs 470 workers across the globe.

What is Revance Therapeutics' official website?

The official website for Revance Therapeutics is www.revance.com.

Where are Revance Therapeutics' headquarters?

Revance Therapeutics is headquartered at 7555 GATEWAY BLVD., NEWARK CA, 94560.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at (615) 724-7755, via email at [email protected], or via fax at 510-742-3401.

This page was last updated on 11/30/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.